Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer : Results from the European Prospective Investigation into Cancer and Nutrition study. / Pham, Thu Thi; Nimptsch, Katharina; Aleksandrova, Krasimira; Jenab, Mazda; Fedirko, Veronika; Wu, Kana; Eriksen, Anne Kirstine; Tjønneland, Anne; Severi, Gianluca; Rothwell, Joseph; Kaaks, Rudolf; Katzke, Verena; Catalano, Alberto; Agnoli, Claudia; Masala, Giovanna; De Magistris, Maria Santucci; Tumino, Rosario; Vermeulen, Roel; Aizpurua, Amaia; Trobajo-Sanmartín, Camino; Chirlaque, María-Dolores; Sánchez, Maria-Jose; Lu, Sai San Moon; Cross, Amanda J; Christakoudi, Sofia; Weiderpass, Elisabete; Pischon, Tobias.
In: International Journal of Cancer, Vol. 154, No. 9, 2024, p. 1596-1606.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer
T2 - Results from the European Prospective Investigation into Cancer and Nutrition study
AU - Pham, Thu Thi
AU - Nimptsch, Katharina
AU - Aleksandrova, Krasimira
AU - Jenab, Mazda
AU - Fedirko, Veronika
AU - Wu, Kana
AU - Eriksen, Anne Kirstine
AU - Tjønneland, Anne
AU - Severi, Gianluca
AU - Rothwell, Joseph
AU - Kaaks, Rudolf
AU - Katzke, Verena
AU - Catalano, Alberto
AU - Agnoli, Claudia
AU - Masala, Giovanna
AU - De Magistris, Maria Santucci
AU - Tumino, Rosario
AU - Vermeulen, Roel
AU - Aizpurua, Amaia
AU - Trobajo-Sanmartín, Camino
AU - Chirlaque, María-Dolores
AU - Sánchez, Maria-Jose
AU - Lu, Sai San Moon
AU - Cross, Amanda J
AU - Christakoudi, Sofia
AU - Weiderpass, Elisabete
AU - Pischon, Tobias
N1 - © 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
PY - 2024
Y1 - 2024
N2 - Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine-Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HRQ4vsQ1 = 0.95, 95% CI: 0.73-1.23; Ptrend = .97; and HRper doubling of resistin concentration = 1.00; 95% CI: 0.84-1.19; P = .98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression.
AB - Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine-Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HRQ4vsQ1 = 0.95, 95% CI: 0.73-1.23; Ptrend = .97; and HRper doubling of resistin concentration = 1.00; 95% CI: 0.84-1.19; P = .98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression.
U2 - 10.1002/ijc.34830
DO - 10.1002/ijc.34830
M3 - Journal article
C2 - 38200695
VL - 154
SP - 1596
EP - 1606
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 9
ER -
ID: 379581061